The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.

ABSTRACT: The identification of prognostic biomarkers is a priority for patients suffering from high-grade serous ovarian cancer (SOC), which accounts for >70% of ovarian cancer (OC) deaths. Meanwhile, borderline ovarian cancer (BOC) is a low malignancy tumor and usually patients undergo surgery with low probabilities of recurrence. However, SOC remains the most lethal neoplasm due to the lack of biomarkers for early diagnosis and prognosis. In this regard, BORIS (CTCFL), a CTCF paralog, is a promising cancer biomarker that is overexpressed and controls transcription in several cancer types, mainly in OC. Studies suggest that BORIS has an important function in OC by altering gene expression, but the effect and extent to which BORIS influences transcription in OC from a genome-wide perspective is unc

SUBMITTER: Salgado-Albarran M 

PROVIDER: S-EPMC6690894 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature